Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

AIDS

Volumn 23, Issue 9, 2009, Pages 1171-1173

  Bénard, Antoine ^a   Damond, Florence ^b   Campa, Pauline ^b   Peytavin, Gilles ^b   Descamps, Diane ^b   Lascoux Combes, Caroline ^b   Taieb, Audrey ^a   Simon, François ^b   Autran, Brigitte ^c   Brun Vézinet, Françoise ^b   Chêne, Geneviève ^a   Matheron, Sophie ^b  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; GENE MUTATION; GYNECOMASTIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-2; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; TREATMENT OUTCOME;

EID: 67651123217     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832949f0     Document Type: Article

References (15)

1. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al., ANRS CO5 HIV2 Cohort Study group. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459-462.
2. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-468.
3. Desbois D, Roquebert B, Peytavin G, Damond F, Coll in G, Bénard A, et al., French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-1548.
4. Damond F, Gueudin M, Pueyo S, Farfara I, Robertson DL, Descamps D, et al. Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J Clin Microbiol 2002; 40:3654-3659.
5. Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J din Microbiol 2005; 43:4234-4236.
6. Plantier JC, Gueudin M, de Oliveira F, Damond F, Lemée V, Brun-Vézinet F, et al. Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR. J din Microbiol 2004; 42:5866-5870.
7. Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J din Microbiol 2005; 43:484-487.
8. Matheron S. HIV-2 infection: a call for controlled trials. AIDS 2008; 22:2073-2074.
9. Adjé-Toure CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. AIDS 2003; 17 (Suppl 3):S49-S54.
10. Rodés B, Sheldon J, Toro C, Jiménez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006; 57:709-713.
11. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
12. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
13. Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al., KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368:476-482.
14. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al., AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
15. Gottlieb GS, Eholie SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2; infection in West Africa. AIDS 2008; 22:2069-2072.